Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
F 4.05 -3.57% -0.15
AGEN closed down 3.57 percent on Friday, November 1, 2024, on 1.19 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 5
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Down 3% about 19 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
New 52 Week Low about 20 hours ago
60 Minute Opening Range Breakdown about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Agenus Inc. Description

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Alzheimer's Disease Non Small Cell Lung Cancer Melanoma Vaccines Small Cell Lung Cancer Vaccination Carcinoma Malaria Glioma Herpes Cancer Vaccine Renal Cell Carcinoma Shingles Experimental Cancer Treatments Metastatic Melanoma Genital Herpes Treatment Of Malaria

Is AGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.688
52 Week Low 4.0
Average Volume 354,413
200-Day Moving Average 9.94
50-Day Moving Average 5.03
20-Day Moving Average 4.48
10-Day Moving Average 4.37
Average True Range 0.29
RSI (14) 32.89
ADX 23.95
+DI 11.55
-DI 28.21
Chandelier Exit (Long, 3 ATRs) 4.05
Chandelier Exit (Short, 3 ATRs) 4.86
Upper Bollinger Bands 4.82
Lower Bollinger Band 4.14
Percent B (%b) -0.13
BandWidth 15.19
MACD Line -0.25
MACD Signal Line -0.26
MACD Histogram 0.0021
Fundamentals Value
Market Cap 1.55 Billion
Num Shares 381 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -5.00
Price-to-Sales 2.83
Price-to-Book 218.61
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.55
Resistance 3 (R3) 4.59 4.46 4.47
Resistance 2 (R2) 4.46 4.34 4.44 4.44
Resistance 1 (R1) 4.26 4.26 4.19 4.22 4.41
Pivot Point 4.13 4.13 4.10 4.11 4.13
Support 1 (S1) 3.92 4.00 3.86 3.88 3.69
Support 2 (S2) 3.79 3.92 3.77 3.66
Support 3 (S3) 3.59 3.79 3.63
Support 4 (S4) 3.55